Recipharm’s rights issue fully subscribed

Not for release, publication or distribution, directly or indirectly, in or into
the United States, Canada, Australia, Japan, Hong Kong, New Zealand, South
Africa or any other jurisdiction where such distribution of this press release
would be subject to legal restrictions
Recipharm AB’s (publ) (“Recipharm” or the “Company”) new share issue with
preferential right for the Company’s shareholders (“the rights issue”) has been
fully subscribed. The subscription period for the rights issue ended on 7 June
2016. In the rights issue, 2,537,142 class A shares and 7,241,127 class B
shares, corresponding to approximately 99.7 per cent of the offered shares, have
been subscribed for with subscription rights.

In addition, subscriptions corresponding to 6,796,500 class B shares have been
received for subscription with second priority preferential right or without
preferential right, corresponding to approximately 93.4 per cent of the total
number of class B shares in the rights issue. Those who have applied for
subscription of shares without subscription rights will be allocated shares
according to the principles outlined in the prospectus. Such allocation of
shares has only been made to those who have subscribed for shares with second
priority preferential right.

Notification regarding allocation of class B shares that have been subscribed
with second priority preferential right will take place around 13 June 2016 by
distribution of a settlement note to those who have been allocated
shares. Subscribed and allocated new class B shares shall be paid in cash at the
latest on the settlement day, 16 June 2016, in accordance with the instructions
on the settlement note. Nominee registered shareholders will receive
notification regarding allocation of shares in accordance with the respective
nominee’s procedures. Only those who are allocated shares will be notified.

The rights issue provides Recipharm with proceeds of approximately SEK 805
million before deduction of issue costs. Pursuant to the rights issue,
Recipharm’s share capital will increase by SEK 4,905,533 from SEK 26,703,233 to
SEK 31,608,766.[1] The total number of shares will increase by 9,811,066 shares,
of which 2,537,142 are new class A shares and 7,273,924 are new class B shares,
to a total of 63,217,532 shares of which 15,222,858 are class A shares,
47,494,674 are class B shares and 500,000 are class D shares.1

The new class A and class B shares subscribed for with subscription rights are
expected to be registered with the Swedish Companies Registration Office around
14 June 2016 and the new class B shares are expected to commence trading on
Nasdaq Stockholm on 16 June 2016. The class B shares subscribed for without
subscription rights are expected to start trading on Nasdaq Stockholm on 22 June
2016.

For further information please visit www.recipharm.com or contact:

Thomas Eldered, CEO, +46 8 602 52 10

Björn Westberg, CFO, ir@recipharm.com, +46 8 602 46 20

This information is published in accordance with the Swedish Securities Market
Act, the Swedish Financial Instruments Trading Act and/or the regulations of
Nasdaq Stockholm. This information was submitted for publication on 13 June
2016, at 08:00 am CET.

About Recipharm
Recipharm is a leading CDMO (Contract Development and Manufacturing
Organisation) in the pharmaceutical industry employing some 3,500 employees.
Recipharm offers manufacturing services of pharmaceuticals in various dosage
forms, production of clinical trial material and APIs, and pharmaceutical
product development. Recipharm manufactures several hundred different products
to customers ranging from Big Pharma to smaller research- and development
companies. Recipharm’s turnover is approximately SEK 5.0 billion and the Company
operates development and manufacturing facilities in France, Germany, India,
Israel, Italy, Portugal, Spain, Sweden and the UK and is headquartered in
Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and our services, please visit
www.recipharm.com

Financial and legal advisers

DNB Markets, Handelsbanken Capital Markets and Swedbank Corporate Finance are
acting as financial advisors and Setterwalls Advokatbyrå AB is acting as legal
advisor to Recipharm in relation to the rights issue.

Important information

The information in this press release does not constitute an offer to acquire,
subscribe for or otherwise trade in shares, subscription rights or other
securities in Recipharm. Any invitation to the persons concerned to subscribe
for shares in Recipharm will only be made through the prospectus that Recipharm
published on 19 May 2016.

This press release may not be released, published or distributed, directly or
indirectly, in or into the United States, Australia, Canada, Hong Kong, Japan,
New Zealand, South Africa or any other jurisdiction where such action is wholly
or partially subject to legal restrictions or where such action would require
additional prospectuses, registrations or other actions in addition to what
follows from Swedish law. Nor may the information in this press release be
forwarded, reproduced or disclosed in a manner that contravenes such
restrictions or would entail such requirements. Failure to comply with this
instruction may result in a violation of applicable securities laws.

No subscription rights, BTAs (interim shares) or new shares have or will be
registered under the U.S. Securities Act of 1933, as amended, (“Securities
Act”), or securities legislation in any state or other jurisdiction in the
United States and may not be offered or sold, directly or indirectly, in or into
the United States, except pursuant to an available exemption from the
registration requirements of the Securities Act and in compliance with the
securities laws of any state or other jurisdiction of the United States.

This press release may contain forward-looking statements which reflect
Recipharm’s current view on future events and financial and operational
development. The words “intend”, “estimate”, “expect”, “may”, “plan”,
“anticipate” or similar expressions regarding indications or prognoses of future
developments or trends and which are not statements based on historical facts
constitute forward-looking information. Although Recipharm believes that these
statements are based on reasonable assumptions and expectations, Recipharm
cannot give any assurances that such statements will materialize. Forward
-looking statements are in its nature involved with both known and unknown risks
and uncertainties, since it is depending on future events and circumstances.
Forward-looking statements do not constitute any representations and warranties
and the outcome could differ materially from the information set out in the
forward-looking statements.

----------------------------------------------------------------------

[1] Taking into account the 631,914 class B shares issued in a directed cash
issue to the subscribtion price of SEK 82 in accordance with the board decision
from 23 May 2016 to the sellers of Kemwell AB, i.e. Kemfin Holdings Private Ltd.
and a minority seller. The directed cash issue raised proceeds of approximately
SEK 52 million to Recipharm, with settlement date on 7 June 2016.
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52
00, Fax 46 8 81 87 03
www.recipharm.com